Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.

MLA

Brandt, Jan, et al. “Successful Short Term Treatment of Severe Undifferentiated Spondyloarthropathy with the Anti-Tumor Necrosis Factor-Alpha Monoclonal Antibody Infliximab.” Journal of Rheumatology, vol. 29, no. 1, Jan. 2002, pp. 118–22. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=ejs19888142&authtype=sso&custid=ns315887.

APA

Brandt, J., Haibel, H., Reddig, J., Sieper, J., & Braun, J. (2002). Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. Journal of Rheumatology, 29(1), 118–122.

Chicago

Brandt, Jan, Hildrun Haibel, Jaqueline Reddig, Joachim Sieper, and Jürgen Braun. 2002. “Successful Short Term Treatment of Severe Undifferentiated Spondyloarthropathy with the Anti-Tumor Necrosis Factor-Alpha Monoclonal Antibody Infliximab.” Journal of Rheumatology 29 (1): 118–22. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=ejs19888142&authtype=sso&custid=ns315887.